Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!
Oncology Times - OncTimes Talk
English - October 13, 2009 19:01 - 6 minutes - 1000 Bytes - ★★★★ - 2 ratingsScience Health & Fitness Medicine oncology cancer medicine health news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome
Next Episode: Program 2, Sunday Dec. 6
Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.